4BASEBIO UK SOCIETAS - Asset Resilience Ratio
4BASEBIO UK SOCIETAS (4BB) has an Asset Resilience Ratio of 0.50% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 4BB strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how 4BASEBIO UK SOCIETAS's Asset Resilience Ratio has changed over time. See net asset quality index of 4BASEBIO UK SOCIETAS to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down 4BASEBIO UK SOCIETAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4BASEBIO UK SOCIETAS (4BB) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX225.00K | 0.5% |
| Total Liquid Assets | GBX225.00K | 0.50% |
Asset Resilience Insights
- Limited Liquidity: 4BASEBIO UK SOCIETAS maintains only 0.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
4BASEBIO UK SOCIETAS Industry Peers by Asset Resilience Ratio
Compare 4BASEBIO UK SOCIETAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for 4BASEBIO UK SOCIETAS (2019–2024)
The table below shows the annual Asset Resilience Ratio data for 4BASEBIO UK SOCIETAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.50% | GBX225.00K ≈ $27.38 |
GBX44.73 Million ≈ $5.44K |
-1.48pp |
| 2023-12-31 | 1.98% | GBX236.00K ≈ $28.71 |
GBX11.92 Million ≈ $1.45K |
-0.07pp |
| 2022-12-31 | 2.05% | GBX240.00K ≈ $29.20 |
GBX11.69 Million ≈ $1.42K |
+0.50pp |
| 2021-12-31 | 1.55% | GBX228.00K ≈ $27.74 |
GBX14.70 Million ≈ $1.79K |
+0.32pp |
| 2020-12-31 | 1.23% | GBX219.00K ≈ $26.65 |
GBX17.81 Million ≈ $2.17K |
-15.74pp |
| 2019-12-31 | 16.97% | GBX196.00K ≈ $23.85 |
GBX1.16 Million ≈ $140.53 |
-- |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more